A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

Table 2

Lipid profile.

Parameter	EZE + Statin	STAT^2	𝑃 Value
			(Between-Group)
	𝑛=34	𝑛=30
Baseline, mmol/L (mean ± SD)
Total cholesterol	4.29±0.62	4.57±0.95	0.161
LDL-C	2.54±0.53	2.77±0.68	0.140
HDL-C	1.06±0.27	1.10±0.32	0.589
Triglycerides	1.66±0.78	1.50±0.66	0.386
Total cholesterol/HDL-C ratio	4.21±1.00	4.67±2.82	0.376
	𝑛=28	𝑛=28
Six weeks, mmol/L (mean ± SD)
Total cholesterol	3.75±1.01	3.99±0.90	0.351
LDL-C	2.08±0.80	2.32±0.57	0.223
HDL-C	1.07±0.30	1.04±0.29	0.738
Triglycerides	1.32±0.53	1.44±0.87	0.547
Total cholesterol/HDL-C ratio	3.64±1.06	4.00±1.03	0.197
	𝑛=29	𝑛=23
Twelve weeks, mmol/L (mean ± SD)*
Total cholesterol	3.55±0.92	3.67±0.50	0.563
LDL-C	1.86±0.63	2.02±0.39	0.294
HDL-C	1.13±0.47	1.02±0.28	0.351
Triglycerides	1.22±0.47	1.38±0.55	0.287
Total cholesterol/HDL-C ratio	3.29±0.77	3.84±1.15	0.046

LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol.
*12 weeks results account for 2 crossovers in treatment assignment, reflecting treatment actually received (Figure 2).